Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 6Head & Neck 2Gynecologic 2Breast 2Thoracic 1Genitourinary 1Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Ovarian Neoplasms 15Uterine Cervical Neoplasms 12Carcinoma, Non-Small-Cell Lung 10Melanoma 9Triple Negative Breast Neoplasms 7Endometrial Neoplasms 7Stomach Neoplasms 6Carcinoma, Transitional Cell 6Carcinoma, Renal Cell 6Squamous Cell Carcinoma of Head and Neck 5Small Cell Lung Carcinoma 5Fallopian Tube Neoplasms 5Colorectal Neoplasms 4Carcinoma, Merkel Cell 4Carcinoma, Hepatocellular 4Neoplasm Metastasis 3Mesothelioma 3Esophageal Neoplasms 3Cholangiocarcinoma 3Vulvar Neoplasms 2Urinary Bladder Neoplasms 2Seminoma 2Sarcoma 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Neoplasms 2Nasopharyngeal Carcinoma 2Lung Neoplasms 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Leukemia, Myeloid, Acute 2

Interventions

Doxorubicin 4Ifosfamide 3Radiotherapy 2Ipilimumab 2Filgrastim 2saracatinib 1perifosine 1pembrolizumab 1fludarabine 1brostallicin 1belinostat 1aldesleukin 1Trabectedin 1Temozolomide 1Sunitinib 1Ritonavir 1Nivolumab 1Mass Spectrometry 1Injections 1Indinavir 1Imatinib Mesylate 1Fluorouracil 1Cyclophosphamide 1Chromatography, High Pressure Liquid 1Chemotherapy, Adjuvant 1CTLA-4 Antigen 1BI 2536 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Histiocytoma, Malignant Fibrous × Ipilimumab × Gynecologic × Clear all
NCT03449108 2026-05-22

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
30 enrolled
BreastEndocrineGynecologicHead & NeckSarcoma

Bone Neoplasms, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Giant Cell Tumor of Bone, Histiocytoma, Malignant Fibrous, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

NCT03752398 2024-07-05

DUET-3

Xencor, Inc.

Phase 1 Completed
198 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Melanoma, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Histiocytoma, Malignant Fibrous, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡